Coherus BioSciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. (CHRS) on September 29, 2021, covering the event date of September 23, 2021. The filing addresses a significant corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
The primary material change reported is the departure of a Director due to death. Samuel Nussbaum, M.D., a member of the Company's Board of Directors, passed away on September 23, 2021.
Management Commentary and Risks
Management expressed deep regret regarding the loss of Dr. Nussbaum and acknowledged his dedicated service to the Company. A press release dated September 29, 2021, was issued to honor his contributions. No specific financial risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investors to Verify
- Confirmation of the vacancy on the Board of Directors following Dr. Nussbaum's passing.
- Any subsequent announcements regarding the appointment of a new director to fill the vacancy.
- Review of the attached press release (Exhibit 99.1) for further details on Dr. Nussbaum's tenure and contributions.